If you are not able to view this e-mail properly, please click here to view it online
World Pharma Today Maqazine
World Pharma Today Linkedin Page World Pharma Today Facebook Page World Pharma Today Twitter Page Weekly Newsletter
Click here to subscribe to our Magazine
ePharma 2017
Top Latest Press Releases
Valeant Pharmaceuticals Announces Results Of Phase 3 Study

Valeant Pharmaceuticals Announces Results Of Phase 3 Study For Psoriasis Treatment IDP-118

Valeant Pharmaceuticals International announced positive results from a second confirmatory pivotal Phase 3, multicenter double-blind, randomized, vehicle-controlled clinical study to assess the safety and efficacy of IDP-118 (halobetasol propionate and tazarotene)...


AbbVie, Genomics Medicine and WuXi NextCODE Announce Population Genomics Alliance

AbbVie , a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organization announced the launch of a long-term strategic alliance...


Catalent To Develop Softgel Capsules For Leading Orphan Disease Candidates

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products that it is to evaluate Jupiter Orphan Therapeutics...

Applying New Approaches for Delivery of Diabetes Medications

Applying New Approaches to Containment and Delivery of Diabetes Medications

Type 2 diabetes awareness is rising in the United States. Public and private health leaders are now offering screenings and patient education sites that discuss “prediabetes,” to detect and treat the disease in its earliest stages.


Visterra doses first patient in phase IIa trial for VIS410 for Influenza A

Visterra, Inc , a clinical-stage biopharmaceutical company announced that the first patient was dosed in a Phase 2a clinical trial of VIS410, a monoclonal antibody in development for the treatment of hospitalized patients with influenza A, regardless of the viral strain.


Maverick Therapeutics, Takeda pharma join to drive T-cell Engagement therapeutics for cancer

Maverick Therapeutics Inc , an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited announced that they have entered a collaboration to develop Maverick’s T-cell engagement platform ...


For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here


For the latest visit: www.worldpharmatoday.com

World Pharma Today